Drugging many pharmaceutically relevant proteins remains a challenge, as traditional medicines such as biologics have difficulty entering cells and small molecules do not exhibit sufficient binding to numerous protein surfaces. Pure-DEL discovers orally available macrocycles for challenging targets using its proprietary drug discovery platform, which for the first time allows creating very large libraries (>1 billion molecules) of chemically synthesized complex natural product-like macrocycles to yield orally bioavailable ligands, usable against difficult targets. Pure-DEL is are a team of four scientists from ETH who co-developed Pure-DEL technology with backgrounds in chemistry and biotechnology.